BR0210391A - Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto - Google Patents

Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto

Info

Publication number
BR0210391A
BR0210391A BR0210391-5A BR0210391A BR0210391A BR 0210391 A BR0210391 A BR 0210391A BR 0210391 A BR0210391 A BR 0210391A BR 0210391 A BR0210391 A BR 0210391A
Authority
BR
Brazil
Prior art keywords
compound
patient
disease
treating
methods
Prior art date
Application number
BR0210391-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Shon R Pulley
James P Beck
Ruth E Tenbrink
Jon S Jacobs
Original Assignee
Elan Pharm Inc
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Upjohn Co filed Critical Elan Pharm Inc
Publication of BR0210391A publication Critical patent/BR0210391A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
BR0210391-5A 2001-06-12 2002-06-12 Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto BR0210391A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29750501P 2001-06-12 2001-06-12
US33308201P 2001-11-19 2001-11-19
PCT/US2002/018719 WO2002100399A1 (en) 2001-06-12 2002-06-12 Macrocycles useful in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
BR0210391A true BR0210391A (pt) 2004-06-15

Family

ID=26970188

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210391-5A BR0210391A (pt) 2001-06-12 2002-06-12 Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto

Country Status (6)

Country Link
US (2) US7067507B2 (enExample)
EP (1) EP1395257A1 (enExample)
JP (1) JP2005505506A (enExample)
BR (1) BR0210391A (enExample)
CA (1) CA2450167A1 (enExample)
WO (1) WO2002100399A1 (enExample)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039156A1 (es) * 2002-03-28 2005-02-09 Novartis Ag Amidas del acido piperidinilamino sulfamico o piperazinil sulfamico y su uso para la manufactura de un medicamento en enfermedades mediadas por la accion de la sulfatasa esteroide
CA2485167A1 (en) * 2002-05-07 2003-11-20 The Government Of The United States Of America Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
ATE421526T1 (de) * 2002-06-11 2009-02-15 Lilly Co Eli Prodrugs von exzitatorischen aminosäuren
JP4745661B2 (ja) * 2002-08-22 2011-08-10 大日本住友製薬株式会社 統合失調症治療剤
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) * 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
AU2004204692B2 (en) 2003-01-07 2009-07-09 Merck & Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
DE10315572A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
DE10315571A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
DE10315573A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
DE10315569A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en) * 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
EP2210612B1 (en) 2003-06-18 2016-10-05 Ocera Therapeutics, Inc. Macrocyclic antagonists of the motilin receptor
EP1637530A4 (en) 2003-06-23 2009-04-01 Dainippon Sumitomo Pharma Co THERAPEUTIC AGENT FOR SENILE DEMENTIA
CA2529790A1 (en) * 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds
CA2549869C (en) * 2003-12-18 2015-05-05 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
HRP20040104A2 (en) * 2004-01-30 2005-10-31 Pliva-Istra�iva�ki institut d.o.o. Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
ATE437880T1 (de) * 2004-02-04 2009-08-15 Neurosearch As Dimere azacyclische verbindungen und deren verwendung
NZ548180A (en) * 2004-02-04 2010-04-30 Neurosearch As Diazabicyclic aryl derivatives as cholinergic receptor modulators and nicotinic acetylcholine receptor ligands
EP2357474A1 (en) * 2004-02-20 2011-08-17 Dainippon Sumitomo Pharma Co., Ltd. Lurasidone for use in the treatment of memory or learning dysfunction by schizophrenia
CA2558034A1 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
CA2561945A1 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3 receptor modulators
CN1972914A (zh) * 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
JP2008505930A (ja) 2004-07-09 2008-02-28 エラン ファーマシューティカルズ，インコーポレイテッド オキシム誘導体置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US20060035939A1 (en) * 2004-07-14 2006-02-16 Japan Tobacco Inc. 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
JP4018739B2 (ja) * 2004-07-15 2007-12-05 日本たばこ産業株式会社 縮合ベンズアミド化合物及びバニロイド受容体１型（ｖｒ１）活性阻害剤
US7494986B2 (en) * 2004-07-20 2009-02-24 Bristol-Myers Squibb Company Cycloalkylamine derivatives as NK-1/SSRI antagonists
CN101027297B (zh) * 2004-07-28 2010-09-08 先灵公司 大环β-分泌酶抑制剂
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
US20080166332A1 (en) * 2004-08-27 2008-07-10 Elan Pharmaceuticals, Inc. Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
JP4912314B2 (ja) * 2004-10-26 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 因子Ｘａ化合物
JP2008520670A (ja) * 2004-11-17 2008-06-19 メルク エンド カムパニー インコーポレーテッド アルツハイマー病の治療のための大環状第三アミンβ−セクレターゼ阻害剤
ATE517085T1 (de) * 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
EP1817312B1 (en) * 2004-11-23 2011-06-08 Merck Sharp & Dohme Corp. Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
DK1836179T3 (en) * 2004-12-30 2015-05-26 Janssen Pharmaceutica Nv PIPERIDINE AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FAT ACID AMIDE HYDRALASE (FAAH) FOR THE TREATMENT OF ANCIENT, PAIN AND OTHER CONDITIONS
GB0500683D0 (en) * 2005-01-13 2005-02-23 Novartis Ag Organic compounds
RU2007130794A (ru) * 2005-01-13 2009-02-20 Новартис АГ (CH) Макроциклические соединения для применения в качестве ингибиторов bace
GB0504960D0 (en) * 2005-03-10 2005-04-20 Arakis Ltd Benzoxazocines
CA2604291A1 (en) 2005-04-08 2006-10-19 Comentis, Inc. Compounds which inhibit beta-secretase activity and methods of use thereof
EA017545B1 (ru) * 2005-06-30 2013-01-30 Янссен Фармацевтика Н.В. Циклические анилино-пиридинотриазины в качестве ингибиторов gsk-3
WO2007016496A2 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
DE602006020773D1 (de) 2005-10-25 2011-04-28 Janssen Pharmaceutica Nv Als inhibitoren von beta-sekretase (bace) geeignete 2-amino-3,4-dihydropyridoä3,4-düpyrimidinderivate
EP1948630A2 (en) * 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
EP1963259B1 (en) * 2005-12-15 2012-02-15 AstraZeneca AB Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
DE102005062986A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
GB0526614D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
WO2007092846A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007092839A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
US7868022B2 (en) 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
EP1987033B1 (en) * 2006-02-14 2010-08-25 NeuroSearch A/S Diazabicycloalkane derivatives and their medical use
KR20080109841A (ko) * 2006-03-10 2008-12-17 뉴로젠 코포레이션 피페라지닐 옥소알킬 테트라히드로이소퀴놀린 및 관련유사체
US7759331B2 (en) * 2006-03-10 2010-07-20 Janssen Pharmaceutica Nv Pyridine-containing macroheterococylic compounds as kinase inhibitors
WO2007110363A1 (en) * 2006-03-24 2007-10-04 Neurosearch A/S Novel guanidine derivatives and their medical use
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
EP2029594B1 (en) * 2006-05-23 2010-10-20 NeuroSearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
US7915272B2 (en) * 2006-05-30 2011-03-29 Neurosearch A/S 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use
CN102417480B (zh) * 2006-06-01 2015-08-26 塞诺菲-安万特股份有限公司 作为蛋白酶抑制剂的螺环腈类
ES2569428T3 (es) * 2006-07-13 2016-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina como MTKI
RU2009105762A (ru) * 2006-07-20 2010-08-27 Новартис АГ (CH) Макроциклические соединения, применимые в качестве ингибиторов васе
EP2046760A1 (en) * 2006-07-20 2009-04-15 Novartis AG Macrocyclic lactams
CA2679735A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
US20100063013A1 (en) * 2007-03-26 2010-03-11 Renata Oballa Cathepsin cysteine protease inhibitors
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
UA100983C2 (ru) * 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
JP2010536726A (ja) * 2007-08-17 2010-12-02 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体リガンドとして有用な新規１，４−ジアザ−ビシクロ〔３．２．２〕ノニルヘテロアリール誘導体
JP2010536725A (ja) * 2007-08-17 2010-12-02 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体リガンドとして有用な新規１，４−ジアザ−ビシクロ〔３．２．２〕ノニルオキサジアゾリル誘導体
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8883776B2 (en) * 2007-11-20 2014-11-11 Janssen Pharmaceutica N.V. Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor
US8648085B2 (en) * 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
MX2010008202A (es) 2008-01-28 2010-12-06 Janssen Pharmaceutica Nv Derivados de tio-2-aminoquinolina 6-sustituida utiles como inhibidores de beta-secretasa (bace).
WO2009097401A1 (en) 2008-01-29 2009-08-06 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2009143153A1 (en) * 2008-05-23 2009-11-26 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine h3 receptor
BRPI0918527A2 (pt) 2008-09-08 2015-12-01 Boehring Ingelheim Internat Gmbh compostos para o tratamento de disturbios do cns
AU2010230290B2 (en) 2009-03-31 2013-03-14 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A modulators
WO2010128685A1 (en) * 2009-05-07 2010-11-11 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
BRPI1015043A2 (pt) * 2009-06-19 2019-07-09 Abbott Lab derivados de diazahomoadamantano e métodos de uso dos mesmos
HUE028684T2 (en) * 2009-06-19 2016-12-28 D Western Therapeutics Inst Inc Substituted isoquinoline derivatives
TW201118099A (en) * 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
AP2012006631A0 (en) 2010-08-12 2012-12-31 Boehringer Ingelheim Int 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
ES2380473B1 (es) * 2010-10-13 2013-02-19 Neuron Biopharma, S.A. Compuesto neuroprotector, hipocolesterolémico, antiinflamatorio y antiepiléptico.
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
KR102010222B1 (ko) 2011-04-05 2019-08-13 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
ES2647889T3 (es) * 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
CA2836485C (en) 2011-06-17 2016-12-13 Eli Lilly And Company Bicyclo (3.1.0) hexane- 2,6 -dicarboxylic acid derivatives as mglu2 receptor agonist
ES2619829T3 (es) 2011-11-18 2017-06-27 Heptares Therapeutics Limited Agonistas del receptor muscarínico M1
WO2013168008A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological diseases
US20150141384A1 (en) * 2012-07-03 2015-05-21 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
FR2993563B1 (fr) * 2012-07-20 2015-12-18 Metabrain Res Derives de thiophenes utiles dans le traitement du diabete
WO2014058071A1 (ja) 2012-10-12 2014-04-17 武田薬品工業株式会社 シクロプロパンアミン化合物およびその用途
DK2909204T3 (en) 2012-10-12 2019-04-01 Broad Inst Inc GSK3 INHIBITORS AND METHODS FOR USE THEREOF
WO2014075676A1 (en) * 2012-11-15 2014-05-22 V-Biotek Holding Aps Amines from trigonella foemum - graecum
US9675697B2 (en) * 2013-03-11 2017-06-13 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
AP2016009370A0 (en) * 2014-02-19 2016-08-31 H Lundbeck As 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
US9487511B2 (en) 2014-04-11 2016-11-08 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
SG10201808940WA (en) * 2014-05-09 2018-11-29 Suntory Holdings Ltd Nox inhibitor and nfкb inhibitor containing methoxyflavone
EP3157909B1 (en) * 2014-06-20 2021-04-07 Principia Biopharma Inc. Lmp7 inhibitors
DK3194405T3 (en) * 2014-09-17 2019-04-15 Oncodesign Sa MACROCYCLIC LRRK2 KINase INHIBITORS
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
HUE058204T2 (hu) * 2015-03-03 2022-07-28 Biohaven Therapeutics Ltd Riluzol prodrugok és felhasználásuk
WO2016149248A1 (en) * 2015-03-15 2016-09-22 Emory University N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto
AR105025A1 (es) * 2015-06-19 2017-08-30 Astellas Pharma Inc Compuesto de imidazodiazepina
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
CA2993630A1 (en) 2015-08-12 2017-02-16 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
NZ790226A (en) * 2016-07-11 2025-08-29 Sage Therapeutics Inc C17, C20, and C21 substituted neuroactive steroids and their methods of use
WO2018027193A1 (en) * 2016-08-05 2018-02-08 The Regents Of The University Of California Gp130 modulators
HRP20220962T1 (hr) * 2016-10-05 2022-10-28 Nsc Therapeutics Gmbh Kristalni polimorfi agonista muskarinskog acetilkolinskog receptora
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
EP3571206A1 (en) * 2017-01-20 2019-11-27 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
WO2018167176A1 (en) * 2017-03-15 2018-09-20 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity
SG11201909115WA (en) * 2017-04-05 2019-10-30 Broad Inst Inc Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
EP3625232B1 (en) * 2017-05-19 2021-06-23 Council of Scientific and Industrial Research Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
GB201712567D0 (en) * 2017-08-04 2017-09-20 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for tau aggregates
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2021123883A1 (en) * 2019-12-19 2021-06-24 Latvian Institute Of Organic Synthesis Macrocyclic amides acting as plasmepsin inhbitors for the treatment of malaria

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM982594A0 (en) 1994-12-02 1995-01-05 University Of Queensland, The HIV protease inhibitors

Also Published As

Publication number Publication date
JP2005505506A (ja) 2005-02-24
US7067507B2 (en) 2006-06-27
EP1395257A1 (en) 2004-03-10
CA2450167A1 (en) 2002-12-19
US20030236240A1 (en) 2003-12-25
US20060003978A1 (en) 2006-01-05
US7456163B2 (en) 2008-11-25
WO2002100399A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
BR0210391A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BR0213139A (pt) Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
BR0112000A (pt) Amina, composto, álcool, epóxido, cetona, azida, composição, uso de uma amina, métodos de tratamento de um paciente, de inibição da atividade da beta-secretase, de clivagem da proteìna precursora de amilóide e da produção de peptìdeo amilóide e de placa beta-amilóide em um animal, de tratamento ou prevenção de uma doença distinguida por depósitos de beta-amilóide no cérebro e de produção de um complexo de beta-secretase, e, kit
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
BR0111980A (pt) Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda
BR0211122A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0407618A (pt) derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
NO994016L (no) Heterocykliske forbindelser og deres anvendelse for inhibering av <beta>amyloidpeptid
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
BRPI0412893A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
BR0213743A (pt) Métodos de tratar ou prevenir mal de alzheimer e uma doença, de tratar um indivìduo que tenha, ou de prevenir que um indivìduo contraia, uma doença ou condição, de inibir a atividade de beta-secretase, a clivagem de um isótipo de protéina precursora de amilóide e a produção de peptìdeo beta amilóide e de placa beta-amilóide em um animal e de produzir um complexo de beta-secretase, uso de um composto e composição
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
BR0113590A (pt) 7-oxo-piridopirimidinas
WO2002100818A3 (en) Aminediols as agents for the treatment of alzheimer's disease
BR0214359A (pt) Método para tratar ou prevenir o mal de alzheimer e uma doença e para tratar um paciente que tem, ou para prevenir que um paciente adquira uma doença ou condição, para inibir a atividade de beta-secretase, a clivagem de um isotipo de proteìna de precursor amilóide e a produção de peptìdeo e de placa beta-amilóide e para produzir um complexo de beta-secretase, uso de um composto e, composição
BR0011728A (pt) Método de inibir a agregação de proteìna amilóide e imagem de depósitos de amilóide

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO RPI 2108 DE 31/05/2011.